Filter News

David Braun, Head Of Merck KGaA Device Business (MD&S), Joins Cellect's Advisory Board

Published: May 23, 2017

TEL AVIV, Israel, May 23, 2017 /PRNewswire/ --

Cellect Biotechnology Ltd. (Nasdaq: APOP, TASE: APOP), a developer of stem cell technology, announced today that David Braun, Head of Merck Group's Medical Device Business, is joining Cellect's Scientific and Medical Advisory Board.

"We need business professionals to help us move to commercial grounds," said Dr. Shai Yarkoni, Cellect's CEO. "Cellect is advancing aggressively on the medical side but lacks the business experience to construct and execute large transactions with pharmaceutical giants and medical research centers. David provides us with his experience and enthusiasm that will enable Cellect to build a strong commercial business with its groundbreaking stem cell technology."

Mr. Braun has held multiple additional senior-level executive positions at leading biotech and high-tech companies, ranging from global Fortune 500 corporations to growth-oriented organizations, including Biosafe SA, a stem cell separation leader recently acquired by GE, Newell Brands, Logitech, Chiaro Networks and Elbit Systems.

Cellect's advisory board now includes global leaders and experts in the fields of medical research and drug development. Mr. Braun joins:

  • Dr. Corey Cutler, Senior Physician at the US Dana Farber Cancer Institute, and an Associate Professor of Medicine at Harvard Medical School
  • Professor John F. DiPersio, Chief of Oncology at the Washington University School of Medicine in St. Louis
  • Professor Robert Negrin, Medical Director of the Clinical Bone Marrow Transplantation Laboratory and the Division Chief of the Blood and Marrow Transplant Program at Stanford University
  • Professor Dov Zipori, Director of the Helen and Martin Kimmel Institute for Stem Cell Research at the WIS
  • Professor Francesco Dazzi, a specialist in Regenerative and Haematological Medicine and is KHP Lead for Cellular Therapies at King's College London
  • Dr. Susan Alpert, who has served as the Director of Medical Device Assessment in the FDA, as well as Senior VP Regulatory at Medtronic Inc. and C. R. BARD Inc.

About Cellect Biotechnology Ltd.

Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP"). The Company has developed a breakthrough technology for the isolation of stem cells from any given tissue that aims to improve a variety of stem cells applications.

The Company's technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells in quantity and quality that will allow stems cell related treatments and procedures. Cellect's technology is applicable to a wide variety of stem cells related treatments in regenerative medicine and current clinical trials are aimed at the cancer treatment of bone marrow transplantations.

Back to news